img

Global PCSK9 Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global PCSK9 Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

PCSK9 Inhibitors report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PCSK9 Inhibitors market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Clinical Application and Drug Development are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for PCSK9 Inhibitors industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, PCSK9 Inhibitors key manufacturers include Amgen, Eli Lilly, Sanofi, Pfizer, Novartis, Roche, Merck, Alnylam and AstraZeneca, etc. Amgen, Eli Lilly, Sanofi are top 3 players and held % sales share in total in 2022.
PCSK9 Inhibitors can be divided into Epatha(Evolocumab), Praluent(Alirocumab), Bococizumab and Others, etc. Epatha(Evolocumab) is the mainstream product in the market, accounting for % sales share globally in 2022.
PCSK9 Inhibitors is widely used in various fields, such as Clinical Application, Drug Development and Other,, etc. Clinical Application provides greatest supports to the PCSK9 Inhibitors industry development. In 2022, global % sales of PCSK9 Inhibitors went into Clinical Application filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PCSK9 Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Amgen
Eli Lilly
Sanofi
Pfizer
Novartis
Roche
Merck
Alnylam
AstraZeneca
Affiris
BMS
Ionis Pharmaceuticals
Cyon Therapeutics
Daiichi Sankyo
Segment by Type
Epatha(Evolocumab)
Praluent(Alirocumab)
Bococizumab
Others

Segment by Application


Clinical Application
Drug Development
Other

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the PCSK9 Inhibitors market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of PCSK9 Inhibitors, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the PCSK9 Inhibitors industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of PCSK9 Inhibitors in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, PCSK9 Inhibitors introduction, etc. PCSK9 Inhibitors Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of PCSK9 Inhibitors market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 PCSK9 Inhibitors Market Overview
1.1 PCSK9 Inhibitors Product Overview
1.2 PCSK9 Inhibitors Market Segment by Type
1.2.1 Epatha(Evolocumab)
1.2.2 Praluent(Alirocumab)
1.2.3 Bococizumab
1.2.4 Others
1.3 Global PCSK9 Inhibitors Market Size by Type
1.3.1 Global PCSK9 Inhibitors Market Size Overview by Type (2018-2034)
1.3.2 Global PCSK9 Inhibitors Historic Market Size Review by Type (2018-2024)
1.3.3 Global PCSK9 Inhibitors Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America PCSK9 Inhibitors Sales Breakdown by Type (2018-2024)
1.4.2 Europe PCSK9 Inhibitors Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific PCSK9 Inhibitors Sales Breakdown by Type (2018-2024)
1.4.4 Latin America PCSK9 Inhibitors Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa PCSK9 Inhibitors Sales Breakdown by Type (2018-2024)
2 Global PCSK9 Inhibitors Market Competition by Company
2.1 Global Top Players by PCSK9 Inhibitors Sales (2018-2024)
2.2 Global Top Players by PCSK9 Inhibitors Revenue (2018-2024)
2.3 Global Top Players by PCSK9 Inhibitors Price (2018-2024)
2.4 Global Top Manufacturers PCSK9 Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 PCSK9 Inhibitors Market Competitive Situation and Trends
2.5.1 PCSK9 Inhibitors Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by PCSK9 Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PCSK9 Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into PCSK9 Inhibitors Market
2.8 Key Manufacturers PCSK9 Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 PCSK9 Inhibitors Status and Outlook by Region
3.1 Global PCSK9 Inhibitors Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global PCSK9 Inhibitors Historic Market Size by Region
3.2.1 Global PCSK9 Inhibitors Sales in Volume by Region (2018-2024)
3.2.2 Global PCSK9 Inhibitors Sales in Value by Region (2018-2024)
3.2.3 Global PCSK9 Inhibitors Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global PCSK9 Inhibitors Forecasted Market Size by Region
3.3.1 Global PCSK9 Inhibitors Sales in Volume by Region (2024-2034)
3.3.2 Global PCSK9 Inhibitors Sales in Value by Region (2024-2034)
3.3.3 Global PCSK9 Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global PCSK9 Inhibitors by Application
4.1 PCSK9 Inhibitors Market Segment by Application
4.1.1 Clinical Application
4.1.2 Drug Development
4.1.3 Other
4.2 Global PCSK9 Inhibitors Market Size by Application
4.2.1 Global PCSK9 Inhibitors Market Size Overview by Application (2018-2034)
4.2.2 Global PCSK9 Inhibitors Historic Market Size Review by Application (2018-2024)
4.2.3 Global PCSK9 Inhibitors Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America PCSK9 Inhibitors Sales Breakdown by Application (2018-2024)
4.3.2 Europe PCSK9 Inhibitors Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific PCSK9 Inhibitors Sales Breakdown by Application (2018-2024)
4.3.4 Latin America PCSK9 Inhibitors Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa PCSK9 Inhibitors Sales Breakdown by Application (2018-2024)
5 North America PCSK9 Inhibitors by Country
5.1 North America PCSK9 Inhibitors Historic Market Size by Country
5.1.1 North America PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America PCSK9 Inhibitors Sales in Volume by Country (2018-2024)
5.1.3 North America PCSK9 Inhibitors Sales in Value by Country (2018-2024)
5.2 North America PCSK9 Inhibitors Forecasted Market Size by Country
5.2.1 North America PCSK9 Inhibitors Sales in Volume by Country (2024-2034)
5.2.2 North America PCSK9 Inhibitors Sales in Value by Country (2024-2034)
6 Europe PCSK9 Inhibitors by Country
6.1 Europe PCSK9 Inhibitors Historic Market Size by Country
6.1.1 Europe PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe PCSK9 Inhibitors Sales in Volume by Country (2018-2024)
6.1.3 Europe PCSK9 Inhibitors Sales in Value by Country (2018-2024)
6.2 Europe PCSK9 Inhibitors Forecasted Market Size by Country
6.2.1 Europe PCSK9 Inhibitors Sales in Volume by Country (2024-2034)
6.2.2 Europe PCSK9 Inhibitors Sales in Value by Country (2024-2034)
7 Asia-Pacific PCSK9 Inhibitors by Region
7.1 Asia-Pacific PCSK9 Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific PCSK9 Inhibitors Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific PCSK9 Inhibitors Sales in Value by Region (2018-2024)
7.2 Asia-Pacific PCSK9 Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific PCSK9 Inhibitors Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific PCSK9 Inhibitors Sales in Value by Region (2024-2034)
8 Latin America PCSK9 Inhibitors by Country
8.1 Latin America PCSK9 Inhibitors Historic Market Size by Country
8.1.1 Latin America PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America PCSK9 Inhibitors Sales in Volume by Country (2018-2024)
8.1.3 Latin America PCSK9 Inhibitors Sales in Value by Country (2018-2024)
8.2 Latin America PCSK9 Inhibitors Forecasted Market Size by Country
8.2.1 Latin America PCSK9 Inhibitors Sales in Volume by Country (2024-2034)
8.2.2 Latin America PCSK9 Inhibitors Sales in Value by Country (2024-2034)
9 Middle East and Africa PCSK9 Inhibitors by Country
9.1 Middle East and Africa PCSK9 Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa PCSK9 Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa PCSK9 Inhibitors Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa PCSK9 Inhibitors Sales in Value by Country (2018-2024)
9.2 Middle East and Africa PCSK9 Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa PCSK9 Inhibitors Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa PCSK9 Inhibitors Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Amgen
10.1.1 Amgen Company Information
10.1.2 Amgen Introduction and Business Overview
10.1.3 Amgen PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Amgen PCSK9 Inhibitors Products Offered
10.1.5 Amgen Recent Development
10.2 Eli Lilly
10.2.1 Eli Lilly Company Information
10.2.2 Eli Lilly Introduction and Business Overview
10.2.3 Eli Lilly PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Eli Lilly PCSK9 Inhibitors Products Offered
10.2.5 Eli Lilly Recent Development
10.3 Sanofi
10.3.1 Sanofi Company Information
10.3.2 Sanofi Introduction and Business Overview
10.3.3 Sanofi PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Sanofi PCSK9 Inhibitors Products Offered
10.3.5 Sanofi Recent Development
10.4 Pfizer
10.4.1 Pfizer Company Information
10.4.2 Pfizer Introduction and Business Overview
10.4.3 Pfizer PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Pfizer PCSK9 Inhibitors Products Offered
10.4.5 Pfizer Recent Development
10.5 Novartis
10.5.1 Novartis Company Information
10.5.2 Novartis Introduction and Business Overview
10.5.3 Novartis PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Novartis PCSK9 Inhibitors Products Offered
10.5.5 Novartis Recent Development
10.6 Roche
10.6.1 Roche Company Information
10.6.2 Roche Introduction and Business Overview
10.6.3 Roche PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Roche PCSK9 Inhibitors Products Offered
10.6.5 Roche Recent Development
10.7 Merck
10.7.1 Merck Company Information
10.7.2 Merck Introduction and Business Overview
10.7.3 Merck PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Merck PCSK9 Inhibitors Products Offered
10.7.5 Merck Recent Development
10.8 Alnylam
10.8.1 Alnylam Company Information
10.8.2 Alnylam Introduction and Business Overview
10.8.3 Alnylam PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Alnylam PCSK9 Inhibitors Products Offered
10.8.5 Alnylam Recent Development
10.9 AstraZeneca
10.9.1 AstraZeneca Company Information
10.9.2 AstraZeneca Introduction and Business Overview
10.9.3 AstraZeneca PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.9.4 AstraZeneca PCSK9 Inhibitors Products Offered
10.9.5 AstraZeneca Recent Development
10.10 Affiris
10.10.1 Affiris Company Information
10.10.2 Affiris Introduction and Business Overview
10.10.3 Affiris PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Affiris PCSK9 Inhibitors Products Offered
10.10.5 Affiris Recent Development
10.11 BMS
10.11.1 BMS Company Information
10.11.2 BMS Introduction and Business Overview
10.11.3 BMS PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.11.4 BMS PCSK9 Inhibitors Products Offered
10.11.5 BMS Recent Development
10.12 Ionis Pharmaceuticals
10.12.1 Ionis Pharmaceuticals Company Information
10.12.2 Ionis Pharmaceuticals Introduction and Business Overview
10.12.3 Ionis Pharmaceuticals PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Ionis Pharmaceuticals PCSK9 Inhibitors Products Offered
10.12.5 Ionis Pharmaceuticals Recent Development
10.13 Cyon Therapeutics
10.13.1 Cyon Therapeutics Company Information
10.13.2 Cyon Therapeutics Introduction and Business Overview
10.13.3 Cyon Therapeutics PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Cyon Therapeutics PCSK9 Inhibitors Products Offered
10.13.5 Cyon Therapeutics Recent Development
10.14 Daiichi Sankyo
10.14.1 Daiichi Sankyo Company Information
10.14.2 Daiichi Sankyo Introduction and Business Overview
10.14.3 Daiichi Sankyo PCSK9 Inhibitors Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Daiichi Sankyo PCSK9 Inhibitors Products Offered
10.14.5 Daiichi Sankyo Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 PCSK9 Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 PCSK9 Inhibitors Industrial Chain Analysis
11.4 PCSK9 Inhibitors Market Dynamics
11.4.1 PCSK9 Inhibitors Industry Trends
11.4.2 PCSK9 Inhibitors Market Drivers
11.4.3 PCSK9 Inhibitors Market Challenges
11.4.4 PCSK9 Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 PCSK9 Inhibitors Distributors
12.3 PCSK9 Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Epatha(Evolocumab)
Table 2. Major Company of Praluent(Alirocumab)
Table 3. Major Company of Bococizumab
Table 4. Major Company of Others
Table 5. Global PCSK9 Inhibitors Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global PCSK9 Inhibitors Sales by Type (2018-2024) & (K Units)
Table 7. Global PCSK9 Inhibitors Sales Market Share in Volume by Type (2018-2024)
Table 8. Global PCSK9 Inhibitors Sales by Type (2018-2024) & (US& Million)
Table 9. Global PCSK9 Inhibitors Market Share in Value by Type (2018-2024)
Table 10. Global PCSK9 Inhibitors Price by Type (2018-2024) & (USD/Unit)
Table 11. Global PCSK9 Inhibitors Sales by Type (2024-2034) & (K Units)
Table 12. Global PCSK9 Inhibitors Sales Market Share in Volume by Type (2024-2034)
Table 13. Global PCSK9 Inhibitors Sales by Type (2024-2034) & (US$ Million)
Table 14. Global PCSK9 Inhibitors Sales Market Share in Value by Type (2024-2034)
Table 15. Global PCSK9 Inhibitors Price by Type (2024-2034) & (USD/Unit)
Table 16. North America PCSK9 Inhibitors Sales by Type (2018-2024) & (K Units)
Table 17. North America PCSK9 Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe PCSK9 Inhibitors Sales (K Units) by Type (2018-2024)
Table 19. Europe PCSK9 Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific PCSK9 Inhibitors Sales (K Units) by Type (2018-2024)
Table 21. Asia-Pacific PCSK9 Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America PCSK9 Inhibitors Sales (K Units) by Type (2018-2024)
Table 23. Latin America PCSK9 Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa PCSK9 Inhibitors Sales (K Units) by Type (2018-2024)
Table 25. Middle East and Africa PCSK9 Inhibitors Sales by Type (2018-2024) & (US$ Million)
Table 26. Global PCSK9 Inhibitors Sales by Company (2018-2024) & (K Units)
Table 27. Global PCSK9 Inhibitors Sales Share by Company (2018-2024)
Table 28. Global PCSK9 Inhibitors Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global PCSK9 Inhibitors Revenue Share by Company (2018-2024)
Table 30. Global Market PCSK9 Inhibitors Price by Company (2018-2024) & (USD/Unit)
Table 31. Global PCSK9 Inhibitors Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global PCSK9 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PCSK9 Inhibitors as of 2022)
Table 34. Date of Key Manufacturers Enter into PCSK9 Inhibitors Market
Table 35. Key Manufacturers PCSK9 Inhibitors Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global PCSK9 Inhibitors Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 38. Global PCSK9 Inhibitors Sales by Region (2018-2024) & (K Units)
Table 39. Global PCSK9 Inhibitors Sales Market Share in Volume by Region (2018-2024)
Table 40. Global PCSK9 Inhibitors Sales by Region (2018-2024) & (US$ Million)
Table 41. Global PCSK9 Inhibitors Sales Market Share in Value by Region (2018-2024)
Table 42. Global PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 43. Global PCSK9 Inhibitors Sales by Region (2024-2034) & (K Units)
Table 44. Global PCSK9 Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 45. Global PCSK9 Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 46. Global PCSK9 Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 47. Global PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2034)
Table 48. Global PCSK9 Inhibitors Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 49. Global PCSK9 Inhibitors Sales by Application (2018-2024) & (K Units)
Table 50. Global PCSK9 Inhibitors Sales Market Share in Volume by Application (2018-2024)
Table 51. Global PCSK9 Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 52. Global PCSK9 Inhibitors Sales Market Share in Value by Application (2018-2024)
Table 53. Global PCSK9 Inhibitors Price by Application (2018-2024) & (USD/Unit)
Table 54. Global PCSK9 Inhibitors Sales by Application (2024-2034) & (K Units)
Table 55. Global PCSK9 Inhibitors Sales Market Share in Volume by Application (2024-2034)
Table 56. Global PCSK9 Inhibitors Sales by Application (2024-2034) & (US$ Million)
Table 57. Global PCSK9 Inhibitors Sales Market Share in Value by Application (2024-2034)
Table 58. Global PCSK9 Inhibitors Price by Application (2024-2034) & (USD/Unit)
Table 59. North America PCSK9 Inhibitors Sales by Application (2018-2024) (K Units)
Table 60. North America PCSK9 Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe PCSK9 Inhibitors Sales by Application (2018-2024) (K Units)
Table 62. Europe PCSK9 Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific PCSK9 Inhibitors Sales by Application (2018-2024) (K Units)
Table 64. Asia-Pacific PCSK9 Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America PCSK9 Inhibitors Sales by Application (2018-2024) (K Units)
Table 66. Latin America PCSK9 Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa PCSK9 Inhibitors Sales by Application (2018-2024) (K Units)
Table 68. Middle East and Africa PCSK9 Inhibitors Sales by Application (2018-2024) & (US$ Million)
Table 69. North America PCSK9 Inhibitors Sales by Country (2018-2024) & (K Units)
Table 70. North America PCSK9 Inhibitors Sales Market Share in Volume by Country (2018-2024)
Table 71. North America PCSK9 Inhibitors Sales by Country (2018-2024) & (US$ Million)
Table 72. North America PCSK9 Inhibitors Sales Market Share in Value by Country (2018-2024)
Table 73. North America PCSK9 Inhibitors Sales by Country (2024-2034) & (K Units)
Table 74. North America PCSK9 Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 75. North America PCSK9 Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 76. North America PCSK9 Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 77. Europe PCSK9 Inhibitors Sales by Country (2018-2024) & (K Units)
Table 78. Europe PCSK9 Inhibitors Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe PCSK9 Inhibitors Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe PCSK9 Inhibitors Sales Market Share in Value by Country (2018-2024)
Table 81. Europe PCSK9 Inhibitors Sales by Country (2024-2034) & (K Units)
Table 82. Europe PCSK9 Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 83. Europe PCSK9 Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 84. Europe PCSK9 Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 85. Asia-Pacific PCSK9 Inhibitors Sales by Region (2018-2024) & (K Units)
Table 86. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific PCSK9 Inhibitors Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific PCSK9 Inhibitors Sales by Region (2024-2034) & (K Units)
Table 90. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 91. Asia-Pacific PCSK9 Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 92. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 93. Latin America PCSK9 Inhibitors Sales by Country (2018-2024) & (K Units)
Table 94. Latin America PCSK9 Inhibitors Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America PCSK9 Inhibitors Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America PCSK9 Inhibitors Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America PCSK9 Inhibitors Sales by Country (2024-2034) & (K Units)
Table 98. Latin America PCSK9 Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 99. Latin America PCSK9 Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 100. Latin America PCSK9 Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 101. Middle East and Africa PCSK9 Inhibitors Sales by Country (2018-2024) & (K Units)
Table 102. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa PCSK9 Inhibitors Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa PCSK9 Inhibitors Sales by Country (2024-2034) & (K Units)
Table 106. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 107. Middle East and Africa PCSK9 Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 108. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 109. Amgen Company Information
Table 110. Amgen Introduction and Business Overview
Table 111. Amgen PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 112. Amgen PCSK9 Inhibitors Product
Table 113. Amgen Recent Development
Table 114. Eli Lilly Company Information
Table 115. Eli Lilly Introduction and Business Overview
Table 116. Eli Lilly PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 117. Eli Lilly PCSK9 Inhibitors Product
Table 118. Eli Lilly Recent Development
Table 119. Sanofi Company Information
Table 120. Sanofi Introduction and Business Overview
Table 121. Sanofi PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 122. Sanofi PCSK9 Inhibitors Product
Table 123. Sanofi Recent Development
Table 124. Pfizer Company Information
Table 125. Pfizer Introduction and Business Overview
Table 126. Pfizer PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 127. Pfizer PCSK9 Inhibitors Product
Table 128. Pfizer Recent Development
Table 129. Novartis Company Information
Table 130. Novartis Introduction and Business Overview
Table 131. Novartis PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 132. Novartis PCSK9 Inhibitors Product
Table 133. Novartis Recent Development
Table 134. Roche Company Information
Table 135. Roche Introduction and Business Overview
Table 136. Roche PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 137. Roche PCSK9 Inhibitors Product
Table 138. Roche Recent Development
Table 139. Merck Company Information
Table 140. Merck Introduction and Business Overview
Table 141. Merck PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 142. Merck PCSK9 Inhibitors Product
Table 143. Merck Recent Development
Table 144. Alnylam Company Information
Table 145. Alnylam Introduction and Business Overview
Table 146. Alnylam PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 147. Alnylam PCSK9 Inhibitors Product
Table 148. Alnylam Recent Development
Table 149. AstraZeneca Company Information
Table 150. AstraZeneca Introduction and Business Overview
Table 151. AstraZeneca PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 152. AstraZeneca PCSK9 Inhibitors Product
Table 153. AstraZeneca Recent Development
Table 154. Affiris Company Information
Table 155. Affiris Introduction and Business Overview
Table 156. Affiris PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 157. Affiris PCSK9 Inhibitors Product
Table 158. Affiris Recent Development
Table 159. BMS Company Information
Table 160. BMS Introduction and Business Overview
Table 161. BMS PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 162. BMS PCSK9 Inhibitors Product
Table 163. BMS Recent Development
Table 164. Ionis Pharmaceuticals Company Information
Table 165. Ionis Pharmaceuticals Introduction and Business Overview
Table 166. Ionis Pharmaceuticals PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 167. Ionis Pharmaceuticals PCSK9 Inhibitors Product
Table 168. Ionis Pharmaceuticals Recent Development
Table 169. Cyon Therapeutics Company Information
Table 170. Cyon Therapeutics Introduction and Business Overview
Table 171. Cyon Therapeutics PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 172. Cyon Therapeutics PCSK9 Inhibitors Product
Table 173. Cyon Therapeutics Recent Development
Table 174. Daiichi Sankyo Company Information
Table 175. Daiichi Sankyo Introduction and Business Overview
Table 176. Daiichi Sankyo PCSK9 Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 177. Daiichi Sankyo PCSK9 Inhibitors Product
Table 178. Daiichi Sankyo Recent Development
Table 179. Key Raw Materials Lists
Table 180. Raw Materials Key Suppliers Lists
Table 181. PCSK9 Inhibitors Market Trends
Table 182. PCSK9 Inhibitors Market Drivers
Table 183. PCSK9 Inhibitors Market Challenges
Table 184. PCSK9 Inhibitors Market Restraints
Table 185. PCSK9 Inhibitors Distributors List
Table 186. PCSK9 Inhibitors Downstream Customers
Table 187. Research Programs/Design for This Report
Table 188. Key Data Information from Secondary Sources
Table 189. Key Data Information from Primary Sources
List of Figures
Figure 1. PCSK9 Inhibitors Product Picture
Figure 2. Global PCSK9 Inhibitors Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global PCSK9 Inhibitors Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global PCSK9 Inhibitors Sales Status and Outlook (2018-2034) & (K Units)
Figure 5. Product Picture of Epatha(Evolocumab)
Figure 6. Global Epatha(Evolocumab) Sales YoY Growth (2018-2034) & (K Units)
Figure 7. Product Picture of Praluent(Alirocumab)
Figure 8. Global Praluent(Alirocumab) Sales YoY Growth (2018-2034) & (K Units)
Figure 9. Product Picture of Bococizumab
Figure 10. Global Bococizumab Sales YoY Growth (2018-2034) & (K Units)
Figure 11. Product Picture of Others
Figure 12. Global Others Sales YoY Growth (2018-2034) & (K Units)
Figure 13. Global PCSK9 Inhibitors Sales by Type (2018-2034) & (US$ Million)
Figure 14. Global PCSK9 Inhibitors Sales Market Share by Type in 2022 & 2034
Figure 15. North America PCSK9 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 16. North America PCSK9 Inhibitors Sales Market Share in Value by Type in 2022
Figure 17. Europe PCSK9 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 18. Europe PCSK9 Inhibitors Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Value by Type in 2022
Figure 21. Latin America PCSK9 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 22. Latin America PCSK9 Inhibitors Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by PCSK9 Inhibitors Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by PCSK9 Inhibitors Revenue in 2022
Figure 27. PCSK9 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Clinical Application
Figure 29. Global Clinical Application Sales YoY Growth (2018-2034) & (K Units)
Figure 30. Product Picture of Drug Development
Figure 31. Global Drug Development Sales YoY Growth (2018-2034) & (K Units)
Figure 32. Product Picture of Other
Figure 33. Global Other Sales YoY Growth (2018-2034) & (K Units)
Figure 34. Global PCSK9 Inhibitors Sales by Application (2018-2034) & (US$ Million)
Figure 35. Global PCSK9 Inhibitors Sales Market Share by Application in 2022 & 2034
Figure 36. North America PCSK9 Inhibitors Sales Market Share in Volume by Application in 2022
Figure 37. North America PCSK9 Inhibitors Sales Market Share in Value by Application in 2022
Figure 38. Europe PCSK9 Inhibitors Sales Market Share in Volume by Application in 2022
Figure 39. Europe PCSK9 Inhibitors Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific PCSK9 Inhibitors Sales Market Share in Value by Application in 2022
Figure 42. Latin America PCSK9 Inhibitors Sales Market Share in Volume by Application in 2022
Figure 43. Latin America PCSK9 Inhibitors Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa PCSK9 Inhibitors Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. PCSK9 Inhibitors Manufacturing Cost Structure
Figure 47. PCSK9 Inhibitors Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries